Shukra Pharmaceuticals Ltd — Important, 28-01-2026: Company Update

Shukra Pharmaceuticals' Committee of Directors has approved the allotment of 46.43 lakh Convertible Equity Warrants to promoter category investors at ₹34 per warrant. The company has received approximately ₹3.95 Cr, representing 25% of the total consideration for these warrants. Valued at about ₹15.79 Cr, these warrants can be converted into equity shares within 18 months by paying the remaining 75%. This move strengthens promoter commitment and, upon full conversion, will slightly increase promoter shareholding from 49.73% to 50.26%, bringing in additional funds for the company.